Aerosol Therapy Flashcards

1
Q

What is the 3 ways that medical aerosol can be delivered

A

Atomizer, Nebulizers, and Inhalers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the three purposes of medical aerosol

A

Deliver bland water solutions to the respiratory tract in order to humidify inspired gases

Administer drugs (bronchodilators, anti-inflammatories and antibiotics) to the lungs, throat, or nose

Improved mobilization and clearance of respiratory secretions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is an aerosol?

A

A suspension of solid or liquid particles in a gas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Aerosol Therapy Compared with Other Forms of Administration

A

Administration of drugs by aerosol offers higher local drug concentrations in the lung with lower systemic levels compared with other forms of administration.

Improved therapeutic action with fewer systemic side effects provides a higher therapeutic index.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the main use of Aerosol Therapy

A

Deliver aerosolized drugs to respiratory tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Aerosol Output

A

Weight or mass of aerosol particles produced by aerosol generator (usually per minute)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Aerosol Output in a Nebulizer

A

Mass of aerosol that is generated in a unit of time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is Aerosol Output in a Drug Delivery System

A

Emitted dose describes the mass of a drug leaving the mouthpiece of a nebulizer or inhaler as an inhaler

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the Methods to Measure Aerosol Output

A

Aerosol output can be measure via collect the aerosol leaving the nebulizer on filters or measuring the weight (gravimetric analysis) or quantity of a drug (assay)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Gravimetric Analysis

A

A gravimetric measurement is easier to do but less reliable compared to assay as weight will change with water evaporation while drug mass will not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Drug Assay

A

A drug assay is more reliable measurement of aerosol output and is the quantiy of a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the fundamental principle of aerosol deposition?

A

Only a fraction of the emitted aerosol will be inhaled and only a fraction of what is inhaled will make it to the lungs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is Deposition?

A

• Disposition is when an aerosol leaves its suspension in a gas it will deposit onto a surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Inhaled Mass Vs. Emitted Dose

A

The inhaled mass is the amount of drug that is inhaled

Only a portion of a generated aerosol (emitted dose) from a nebulizer will be inhaled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Respirable Mass

A

The proportion of the drug mass in particles that are small enough (fine-particle fraction) to reach the lower respiratory tract is the respirable mass.

There will be a small percentage of a drug that will be exhaled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the determinants of deposition?

A

Particle size, inspiratory flow rate, flow pattern, respiratory rate, inhaled volume, ratio of inspiration time to expiratory time, and breath holding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How is Aerosol Output measured?

A

By collecting the aerosol that leaves a nebulizer and collects on special filters.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are heterodispersed aerosols?

A

They are aerosols with particles of different sizes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are key mechanisms of aerosol deposition?

A

Inertial impaction, Gravimetric sedimentation, and Brownian diffusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are two methods to measure medical aerosol particle distribution?

A

(1) Cascade impaction, and (2) Laser diffraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What does gravimetric analysis measure?

A

Aerosol weight.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is an aerosol emitted dose?

A

The mass (amount) of the drug leaving the mouthpiece as an aerosol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is aerosol output rate?

A

The mass (amount) of aerosol generated per unit of time. It varies depending on different nebulizers and inhalers used.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the two most common laboratory methods used to measure medical aerosol particle size distribution?

A

Cascade impaction and laser diffraction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is aerosol output?

A

The mass of fluid or drug contained in the aerosol product by a nebulizer. It is the mass of aerosol generated per unit of time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is an Emitted Dose?

A

The mass of drug leaving the mouthpiece of a nebulizer or inhaler as an aerosol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Where aerosol particles are deposited in the respiratory tract depends on what?

A

It depends on their size, shape, and motion and on the physical characteristics of the airways. Key mechanisms causing aerosol deposition include inertial impaction, sedimentation, and Brownian diffusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Why is particle size so important in aerosol therapy?

A

The ability of aerosols to travel through the air, enter the airways, and deposit in the lung is largely based on particle size.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Which of the following best defines an aerosol?

A

A suspension of liquid or solid particles in a gas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The mass of aerosol particles produced by a nebulizer in a given unit time best describes which quality of the aerosol?

A

Output

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Which of the following describes the mass of drug leaving the mouthpiece of a nebulizer as aerosol?

A

Emitted Dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the retention of aerosol particles resulting from contact with respiratory tract mucosa called?

A

Deposition.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What measure is used to identify the particle diameter, which corresponds to the most typical settling behavior of an aerosol?

A

Mean mass aerodynamic diameter (MMAD).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is inertial impaction?

A

When aerosol in motion collides with and are deposited onto a surface. The greater the mass and velocity of a moving droplet, the greater the inertia and tendency of that droplet to continue moving along its set path.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Aerosols occur in nature as what?

A

Pollens, Spores, Dust, Smoke, Fog, and Mist.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

The aim of medical aerosol therapy is to?

A

To deliver a therapeutic dose of the selected agent (drug) to the desired site of action.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is turbulent flow?

A

Turbulent flow is a function of the ability of the patient to inhale the powder with a sufficiently high inspiratory flow rate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the respirable mass?

A

It is the proportion of aerosolized drug of the proper particle size to reach the lower respiratory tract.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Inertial Impactation is the primary mechanism of deposition for what type of particles

A

This is the primary mechanism for particles larger than 5 μm

Occurs in the first 10 generations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Inertial Impaction is a function of what

A

Inertial impaction is a function of particle size (mass) and velocity

There is a direct relationship with mass and velocity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Inertial Impaction and Mass and Velocity

A

The greater the mass and velocity of a particle the greater its inertia and tendency to move in a set path

When a large particle is moving with a gas stream and the stream changes direction the particle tends to remain on the same path and collide with the airway surface

A smaller particle on the other hand will tend to change direction along with the gas stream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Inertial Impaction and Flow

A

Higher the flow of a gas stream the greater the tendency for particle to impact and be deposited in the airways

Quicker particles can’t change direct easily.

Turbulent flow, obstructed airways, and inspiratory flow greater than 30 L/min will increase inertial impaction

Turbulent flow and convoluted passageways in the nose cause most particles larger than 10 μm to impact and become deposited.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Inertial Impaction and Airway Protection

A

Inertial impaction will filter out particles in order to help protect the lower airway from particulates such as dust and pollen

Particles 6 to 10 μm tend to become deposited in the oropharynx and hypopharynx especially due to the turbulent air flow as it passes around the tongue and into the larynx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What does the aerosol particle size depend on?

A

It depends on the substance being nebulized, the method used to generate the aerosol, and the environmental conditions surrounding the particle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What are monodispersed aerosols?

A

Aerosols with particles of similar sizes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What are therapeutic aerosol depositions influenced by?

A

The inspiratory flow rate, the flow pattern, respiratory Rate, inhaled volume, the I:E ratio, and breath-holding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What is gravimetric sedimentation?

A

When aerosol particles settle out of suspension and are deposited due to the pull of gravity. Breath-holding after inhalation increases sedimentation and distribution in the lungs. The greater the mass of a particle, the faster it settles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What are cascade impactors?

A

They are designed to collect aerosols of different size ranges on a series of stages or plates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What is sedimentation?

A

It occurs when aerosol particles settle out of suspension and are deposited owing to gravity. The greater mass of the particle, the faster it settles.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Which of the following is a common method to measure aerosol particle size?

A

Cascade Impaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What is the primary mechanism for deposition of large, high mass particles (greater than 5 um) in the respiratory tract?

A

Inertial Impaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What will increase aerosol deposition by inertial impaction?

A

Variable or irregular passages and turbulent gas flow.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

sedimentation is a function of what

A

Size and time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

sedimentation and Velocities

A

There is increased settling for larger particles with slower velocities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

With normal breathing sedimentation is the primary mechanism of deposition for what

A

particles 1 to 5 μm and will occurs mostly in the central airways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Sedimentation and Time

A

• As sedimentation  with time, an end- inspiratory breath hold maximizes sedimentation
o e.g. a 10 sec breath-hold can  aerosol deposition by ~ 10% and increase the ratio of aerosol deposited in lung parenchyma to central airway by fourfold.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

How are medical aerosols generated in the clinical setting?

A

They are generated with devices that physically disperse matter into small particles and suspend them in gas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What is Brownian diffusion?

A

The primary deposition mechanism for very SMALL particles and will deposit DEEP within the lungs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Breath holding after inhalation of an aerosol does what?

A

It increases the residence time for the particles in the lung and enhances distribution across the lungs and sedimentation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

What is Brownian Diffusion?

A

Brownian Diffusion is the primary mechanism for deposition of small particles (<3 μm) and will occur mainly in the region of the lung where bulk gas flow ceases and particles can reach the alveoli (particle inertia is low)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Small Particle Collisions

A

Small, low mass aerosol particles are easily bounced around by collisions with carrier gas molecules which will result in the deposition to surrounding surfaces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Particles 1 to 0.5 um

A

Particles 1 to 0.5 μm are stable and will remain in suspension and are cleared with the exhaled gas, whereas particles < 0.5 μm have greater retention rate in the lungs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Particle Aging

A

Aging: Process by which an aerosol suspension changes over time.

Particles constantly growing, shrinking, coalescing or falling out of suspension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Aging of an aerosol depends on:

A

o Ambient conditions
o Composition of aerosol
o Initial size of particles
o Time in suspension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Aerosol Particle will change in size based on

A

hygroscopic tendancy or evaporation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

Rate of particel growth

A

inversly porportional to size
Smaller particles grow faster than larger particles
Small water based particles can also shrink when exposed to relatively dry gas
Aerosols are generated in relatively dry ambient conditions and then taken into airway where both temperature and humidity increase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

Optimal Pattern of Inhalation

A

Optimal pattern of inhalation varies with type of aerosol generating device

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

Aerosol Deposition and Airway Obstruction

A

The presence of airway obstruction is one of the greatest factors influencing aerosol deposition.

Total pulmonary deposition is greater in smokers and patients with obstructive airway disease than in healthy persons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

When flow rate is constant deposition is influenced by

A

When inspiratory flow rates are constant, the deposition fraction of monodisperse aerosols increases with increased VT, length of inspiration, and particle size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Scintigraphy

A

Apporach to quantify aerosol deposition where a drug is tagged with a radioactive substance and then a scanner will be used to measure distribution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

What is the Primary Hazard of Aerosol Therapy

A

Adverse reaction to a drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Other Hazards of Aerosol Therapy

A
Infection
Airway reactivity
Systemic effects of bland aerosol 
Drug concentration
Eye Irritation 
Secondhand Exposure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

Aerosol Therapy and Airway Reactivity

A

Cold air and high-density aerosols can cause reactive bronchospasm and increased airway resistance, especially in patients with pre-existing respiratory disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

What Medication are At Risk for resulting in airway reactivity

A

acetylcysteine, antibiotics, steroids, ribavirin, and distilled water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

How to help with airway recativity

A

Administration of bronchodilators before or with administration of these agents may reduce the risk or duration of increased airway resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

What May Increase the Solute concentration

A

During nebulization, the evaporation, heating, baffling, and recycling of drug solutions undergoing jet or ultrasonic nebulization increase solute concentrations.
This increase in concentration usually is time-dependent; the greatest effect occurs when nebulization of medications occurs over extended periods, as in continuous aerosol drug delivery.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Aerosol and Eye Irritation

A

Aerosol administration via a face mask may deposit drug in the eyes and cause eye irritation.

In very rare cases, anticholinergic medications have been suspected to worsen pre-existing eye conditions, such as forms of glaucoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Aerosol Therapy and Second-Hand Exposure

A

Repeated second-hand exposure to bronchodilators is associated with increased risk of occupational asthma.

Unless filters are placed in the expiratory limb, 40% of aerosols produced during mechanical ventilation are exhausted to the air of the intensive care unit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

What Factors Effect the Efficiacy of Aerosol Generated by a Nebulizer

A
Residual "Dead" Volume
Ideal Filling Volume
Tx Time
Gas Source
Flow Rate 
Gas Density
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

Residual ‘Dead’ Volume

A
  • Jet nebulizers do not aerosolize below minimum volume called ‘dead’ volume
  • Dead volume is amount of drug solution remaining in reservoir when device begins to ‘sputter’ and aerosolization ceases
  • ~ 0.5 to 1.0 ml but varies with different devices (always read the device manufacturers specifications)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

Ideal Filling Volume

A

At any given flow rate, Increase volume will increase time of effective nebulization

A volume between 3- 5 ml (or as per manufacturers recommendation) of solution is recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

Treatment Time

A

incresed volume will decrease concentration of drug in residual volume and increase the drug dose to a patient
increase volumes lenthen treatment time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Effect Of Gas Source And Flow Rate

A

Increased flow rate or gas pressure will decrease particle size and shift MMAD lower
Increased flow rate or gas pressure will increase output and shorten treatment time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

Adequate flow rate for SVN

A

6-8 LPM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

Gas Density

A

Affect aerosol production and depsoition
decreased density (ex. heliox) will decrease aerosol impaction resulting in better deposition in the lungs
When Heliox is used output is < than with air or O2 requiring increase in flow to produce comparable weight of aerosol per min
Even though HEliox will incresae the amount of aerosol in lungs it will require high . flows

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

Type of Solution

A

Viscosity and density of medication effects its output and particle size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

Solutions that Tends to Need Modifications

A

Pentamidine

Antibiotics that have different characteristics and viscosity

Gentamicin requires 10- 12 lpm to produce adequately small aerosol particles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Advantages of Aerosolized Medications

A
Rapid onset
Smaller dose
Less systemic side effects
Painless 
Convenient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

How does a large volume ultrasonic nebulizer work?

A

It incorporates air blowers to carry mist to the patient for delivery of bland aerosol therapy or sputum induction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

How do ultrasonic nebulizers work?

A

They use a piezoelectric crystal to produce aerosols. The crystal converts electrical energy into high frequency vibrations which will form oscillation waves and form droplets with break free as fine aerosol particles. Output is directly affected by amplitude setting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

How do you prime an MDI?

A

Shake the device and release one or more sprays into the air when the MDI is new or hasn’t been used in a while.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

How are DPIs categorized?

A

They are categorized by the design of their dose containers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

How often do you assess a patient on continuous nebulization?

A

Assess them every 30 minutes for the first 2 hours then hourly after that for adverse drug responses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

What affects MDI performance and drug delivery?

A

Low temperature decreases the output of the CFC MDI’s. Debris build up on nozzle or actuator orifice reduces the emitted dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

What are beneficial characteristics of using an MDI?

A

They are portable, compact, short tx time, and easy to use.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

Things that will affect lung deposition

A

Substance being nebulized
Method of generating the aerosol
Breathing pattern
Inspiratory flow rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

What are small volume ultrasonic nebulizers used for?

A

The delivery of aerosolized medications (i.e. bronchodilators, antibiotics and anti-inflammatory agents).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

What are sub-hazards to aerosol drug therapy?

A

Infection, airway reactivity, pulmonary and systemic effects of bland aerosols, drug concentration changes during nebulization, and eye irritation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
99
Q

What contributes to aging of aerosols?

A

The composition of aerosol, the initial size of particles, the time in suspension, and the ambient condition.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
100
Q

What happens to the temperature of a solution placed in an ultrasonic nebulizer?

A

The temperature of the solution increases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
101
Q

What is a dry powder inhaler (DPI)?

A

It is a breath-actuated dosing system by which a patient creates the aerosol by drawing air through a dose of finely milled drug powder. The dispersion of powder into respirable particles depends on creation of turbulent flow in inhaler.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
102
Q

The two most common laboratory methods used to measure medical aerosol particle size distribution

A

cascade impaction and laser diffraction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
103
Q

Cascade impactors

A

designed to collect aerosols of different size ranges on a series of stages or plates.
The mass of aerosol deposited on each plate is quantified by drug assay, and a distribution of drug mass across particle sizes is calculated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
104
Q

laser diffraction

A

a computer is used to estimate the range and frequency of droplet volumes crossing the laser beam.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
105
Q

expression of average particle size

A

Because medical aerosols contain particles of many different sizes (heterodisperse), the average particle size is expressed with a measure of central tendency, such as mass median aerodynamic diameter (MMAD) for cascade impaction or volume median diameter (VMD) for laser diffraction.
o These measurement techniques of the same aerosol may report different sizes, so it is important to know which measurement is used.
o The MMAD and VMD both describe the particle diameter in micrometers (μm).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
106
Q

what are the two common ways to quantify particles

A

o The average particle size which is expressed n terms of central tendency
 Mass Median Particle Size (MMAD)
o Variability of particle size in an aerosol
 Geometric Standard Deviation (GSD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
107
Q

Mass Median Aerodynamic Diameter (MMAD)

A

• Mass median aerodynamic diameter (MMAD) is the size where 50% of the mass of particles will be above this size and 50% will be below this size
• MMAD is important to determine which nebulizer to use to deliver medication to a target area
o If you want deposition into small airways you need to use a nebulizer with a lower MMAD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
108
Q

Geometric Standard Deviation (GSD) “The Spread”

A

• The geometric standard deviation (GSD) describes the variability of particle sizes in an aerosol distribution set at 1 standard deviation above or below the median (15.8% and 84.13%).
• The greater the GSD, the wider the range of particle sizes produced by a device.
• GSD < 1.22, aerosol considered monodispersed = single particle size
o Nebulizers that produce monodisperse aerosols are used mainly in laboratory research and in nonmedical industries
• GSD > 1.22, aerosol considered heterodispersed = range of particle sizes
• Most aerosols used in respiratory care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
109
Q

• Particles > 10 microns

A

o Tx nasopharyngeal or oropharyngeal regions e.g. nasal spray for rhinitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
110
Q

• Particles 5- 10 microns

A

o Deposition to more central airways with significant deposition in oropharyngeal region
 Deposits into the large airways, first 6 generations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
111
Q

• Particles 2- 5 microns

A

o Deposition in LRT (last 6 generations)

o More adrenergic receptors in bronchioles (compared to rest of airway) thus increased response with bronchodilators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
112
Q

• Particles 0.8- 3 microns

A

increased delivery of aerosol to lung parenchyma (alveoli)
o Used for anti-infective drugs such as pentamidine where intra-alveolar deposition needed with minimum deposition in airways due to irritation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
113
Q

what is a nebulizer

A

• Nebulizers generate aerosols from solutions and suspensions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
114
Q

3 categories of nebulizers

A

(1) pneumatic jet nebulizers,
(2) USNs,
(3) vibrating mesh (VM) nebulizers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
115
Q

Nebulizers described in terms of their reservoir size.

A

o Small volume nebulizers (SVNs) most commonly used for medical aerosol therapy hold 5 to 20 ml of medication.
o Large volume nebulizers, also known as jet nebulizers, hold up to 200 ml and may be used for either bland aerosol therapy or continuous drug administration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
116
Q

Small Volume Nebulizer

A

Either pneumatic (gas powered) that utilize a jet-shearing principle for creation of an aerosol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
117
Q

Four categories of jet SVNs include

A

Continuous nebulizer with simple reservoir
Continuous nebulizer with collection reservoir bag,
Breath-enhanced nebulizer
Breath- actuated nebulizer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
118
Q

most commonly used SVN

A

• The most commonly used SVN is the constant output design.
o Aerosol is generated continuously, with 30% to 60% of the nominal dose being trapped as residual volume in the nebulizer, and more than 60% of the emitted dose is wasted to the atmosphere.
o Continuous nebulization wastes medication because the aerosol is produced throughout the respiratory cycle and is largely lost to the atmosphere
o Patients with an I:E ratio of40:60 (or1:1.5) lose 60% of the aerosol generated to the atmosphere.
o If 50% of the total dose is emitted from the nebulizer, and 50% of that aerosol is in the respiratory range and 40% of that is inhaled by the patient, less than 10% deposition is commonly measured in adults receiving continuous nebulizer therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
119
Q

How can aerosolized medication be conserved with a sVN

A

• Aerosolized medication can also be conserved with reservoirs.39
o A reservoir on the expiratory limb of the nebulizer conserves drug aerosol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
120
Q

• Factors affecting SVN efficiency are:

A

o Dead Volume – minimum volume required in the reservoir to aerosolize the drug – 0.5 to 1.0 ml - only 35% to 60% of a drug solution is delivered from a SVN before sputter
o Filling Volume and Treatment Time – ideal is 3 to 5 ml at 6 to 8 LPM flow-rate for a treatment time of 10 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
121
Q

Advantages Of SVN

A

• Less technique and device dependent
o Minimal coordination
• Effective with low inspiratory flows and volumes which improve deposition
• Useful in very young, very old, pts in severe distress, debilitated patients
• No breath hold is required, although it can’t hurt
• Patients in severe distress may have high inspiratory flows…we like the fact we can use a “hands free mask” & just continuously administer medication, eventually some medication reaches our intended target site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
122
Q

Disadvantages Of SVN

A
•	Tx times can get lengthy
•	Contamination
•	Wet cold spray with mask delivery
•	External power source
o	Electrical power or compressed gas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
123
Q

Uses of a SVN

A

• Emergency:
o Unable to follow instructions / disoriented
o Tachypneic (> 25 bpm) / unstable respiratory pattern
o Poor inspiratory capacity
o Incapable of breath hold
• Patient preference/home use
• Formulation of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
124
Q

Small Volume Nebulizer With a Reservoir

A
  • Many types of disposable SVNs are packaged with a 6-inch (15-cm) piece of aerosol tubing to be used as a reservoir
  • This may increase inhaled dose by 5% to 10% or increase the inhaled dose from 10% to approximately 11% with the reservoir tube.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
125
Q

Continuous Small Volume Nebulizer With Collection Bag

A
  • Bag reservoirs hold the aerosol generated during exhalation and allow the small particles to remain in suspension for inhalation with the next breath, while larger particles rain out.
  • These additions have been attributed with a 30% to 50% increase in inhaled dose.
  • A collection bag is attached on the expiratory side of the nebulizer “T,” which collects aerosol leaving the SVN when the patient is not actively inhaling.
  • Some of the aerosol in the bag is inhaled with the next inspiration, increasing total dose efficiency.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
126
Q

Breath Enhanced Nebulizers

A

• Breath-enhanced nebulizers generate aerosol continuously, using a system of vents and one-way valves to minimize aerosol waste.
an inspiratory vent allows the patient to draw in air through the nebulization chamber generating and containing aerosolized drug.
• On exhalation, the inlet vent closes, and aerosol exits by a one-way valve near the mouth- piece; this process can increase inhaled mass by 50% over standard continuous nebulizers and reduces aerosol waste to the atmosphere.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
127
Q

nebulizer with constant output

A

• When there is a constant output the drug will be delivered continuously through inspiration and expiration, this means that when expiration is long than inspiration there will be significant losses in the drug amount

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
128
Q

Dosimetric output

A

• With Dosimetric output the drug will only be delivered during inhalation
o Used in PFT laboratories
o Sense inspiration and pulse airflow to the jet orifice and transform a conventional nebulizer into a breath actuated system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
129
Q

Sputtering

A
  • It can be difficult to determine when a nebulizer treatment is complete.
  • Aerosol delivery from a jet nebulizer ceased after the onset of inconsistent nebulization (sputtering)
  • Aerosol output declined by one-half within 20 seconds of the onset of sputtering.
  • The concentration of albuterol in the nebulizer cup increased significantly when the aerosol output declined, and further weight loss in the nebulizer was caused primarily by evaporation. Most consider aerosolization past the point of initial nebulizer sputter ineffective.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
130
Q

SVN Technique

A

• Use of an SVN is less technique-dependent and device-dependent than use of a pMDI or DPI delivery system.
• Slow inspiratory flow optimizes SVN aerosol deposition. However, deep breathing and breath holding during SVN therapy do little to enhance deposition over normal tidal breathing
• Because the nose is an efficient filter of particles larger than 5 μm, many clinicians prefer not to use a mask for SVN therapy.
o As long as the patient is mouth breathing, there is little difference in clinical response between therapy given by mouthpiece and therapy given by mask.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
131
Q

Optimal Technique for Using a SVN

A

• Assess patient for clinical need
• Select mask or mouthpiece
• Use a conserving system
o Thumb port
o Breath actuator
o Reservoir
• Place drug in nebulizer and saline if needed
• Set gas flow to 6 to 10 L/min
• Coach patient to breath slowly through mouth at normal Vt
• Continue treatment until nebulizer sputters
• Rinse neb with sterile water
• Monitor patient between treatments for adverse effects
• Assess outcome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
132
Q

Infection Control Issues

A
  • The CDC recommends that nebulizers be cleaned and disinfected, rinsed with sterile water, or air dried between uses.
  • Jet SVNs have reservoirs that are open to and positioned below the mouthpiece or mask. This allows secretions from the patient to enter the medication cup, contaminating medication.
  • Multidose drug containers have been associated with contamination.
  • After 7 days of nebulizer use five of six multidose containers of medication solutions were found to be contaminated.
  • Refrigerating solutions and discarding syringes every 24 hours eliminated bacterial contamination.
  • Use of single dose ampoules have not been associated with contamination of medications. In addition, some recommend one nebulizer for one treatment.
  • The Cystic Fibrosis Foundation recommends that standard small volume nebulizers should be discarded after each treatment to prevent infection in cyctic fibrosis patients.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
133
Q

ultrasonic NEbulizer Output

A

• High output with small particles sizes and high aerosol densities
• Output is determined by the amplitude setting (some- times user-selected).
o The greater the signal amplitude, the greater the nebulizer output.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
134
Q

ultrasonic Nebulizers and PArticle Size

A

• Particle size is inversely proportional to the frequency of vibrations.
• Frequency is device- specific and is not user-adjustable.
o For example, the DeVilbiss (Somerset, PA) Portasonic nebulizer operating at a frequency of 2.25 MHz produces particles with an MMAD of 2.5 μm, whereas the DeVilbiss Pulmosonic nebulizer operating at 1.25 MHz produces particles in the 4- to 6-μm range
• Particle size and aerosol density also depend on the source and flow of gas conducting the aerosol to the patient.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
135
Q

Ultrasonic Nebulizer and Ventilators

A

Can be placed in line with a ventilator
In contrast to SVNs, USNs do not add extra gas flow to the ventilator circuit during use. This feature reduces the need to change and reset ventilator and alarm settings during aerosol administration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
136
Q

Advantages Of USN

A
  • Small size
  • Rapid nebulization with shorter Tx time
  • Smaller filling volume
  • Portability (batteries)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
137
Q

Disadvantages Of USN

A
  • Expensive
  • Fragility – lack of durability
  • Infection control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
138
Q

Large Volume Ultrasonic Nebulizers

A
  • Large volume USNs (used mainly for bland aerosol therapy or sputum induction) incorporate air blowers to carry the mist to the patient
  • Low flow through the USN is associated with higher mist density.
  • In contrast to jet nebulizers, the temperature of the solution placed in a USN increases during use.
  • As the temperature increases, the drug concentration increases, and proteins can be denatured.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
139
Q

Small Volume ULtrasonic Nebs Vs LArge VOLUme

A

• In contrast to the larger units, some of these systems do not use a couplant compartment; the medication is placed directly into the manifold on top of the transducer.
o The transducer is connected by a cable to a power source, often battery- powered to increase portability.
• These devices have no blower; the patient’s inspiratory flow draws the aerosol from the nebulizer into the lung.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
140
Q

Medications for Small Volume Ultrasonic Nebulizers

A

wide variety of formulations ranging from bronchodilators to anti-inflammatory agents and antibiotics.

141
Q

Small Volume Ultrasonic Nebulizers Budesonide

A

Suspensions such as budesonide may not nebulize well with USNs, because large suspension aerosol particles that are larger than the aerosol particles remain in the medication cup.

142
Q

Advantages of Small Volume Ultrasonic Nebulizers

A

• Use of a small volume USN may increase available respirable mass for designs with less residual drug volume than SVNs; this may reduce the need for a large quantity of diluent to ensure delivery of the drugs.
o However, sometimes the theoretical advantages of the ultrasonic devices are outweighed by relatively high purchase costs and poor reliability.
• Small volume USNs have been used to administer undiluted bronchodilators to patients with severe bronchospasm. Because the nebulizers have minimal residual drug volume, the treatment time is reduced with smaller volumes; however, it may be increased with standard dosing volumes.

143
Q

Types of Vibrating Mesh Nebulizers

A

Active and Passive

144
Q

Active Vibrating Mesh Nebulizers

A

An active VM neb is a dome shaped aperture plate that is surronded with a piezoceramic element
When electrical energy is applied it will move the aperture plate up and down creating an electronic pump whih breaks the liquid into fine droplets

145
Q

MMAD of particles using Active VM Nebs

A

The exit velocity of the aerosol is low (<4 m/sec), and the particle size can range from 3 to 4 μm (MMAD), varying with the exit diameter of the apertures

146
Q

Passive VM

A

Passive VM nebulizers use a mesh separated from an ultrasonic horn by the liquid solution for nebulization.

A piezoelectric transducer vibrates the ultrasonic horn, which pushes fluid through the mesh.

147
Q

Percentage of Aersol from Passive VM

A

The residual drug volumes with either type of VM nebulizer range from 0.1 to 0.4 ml
Because a greater percentage of standard unit doses is emitted as aerosol, care should be exercised when transitioning to these devices to ensure that the higher dose does not create adverse effects.

148
Q

What do New Nebulizer Aim to Do

A

Low-velocity (soft mist) aerosol, smaller particle size distribution, and systems that minimize residual volume of medication left in the nebulizer substantially improve aerosol device efficiency.

149
Q

Respimat

A

The Respimat soft mist inhaler that uses mechanical energy to create an aerosol from liquid solutions to produce a low-velocity spray (10 mm/sec) that delivers a unit dose of drug in a single actuation.

To operate the device, patients twist the body of the device to load an internal spring, place the mouthpiece of the Respimat between the lips, and press a button to release the drug through a uniblock to create the aerosol, which is released over 1.1 to 1.4 seconds, depending on the formulation configuration.

The Respimat requires hand-breath coordination on the part of the patient, as does a pMDI, but because of the longer aerosolization time, it seems more likely that the patient will get a greater percent of emitted dose despite coordination issues.

Because of the small particle size and low-velocity spray, pulmonary deposition of 40% is independent of inspiratory flows with oral deposition (40%) half the oral deposition with most pMDIs and DPIs (80%).

150
Q

SVN Nebulizer Design

A
  • A typical SVN is powered by a high-pressure stream of gas directed through a restricted orifice (the jet).
  • The gas stream leaving the jet passes by the opening of a capillary tube immersed in solution.
  • Because it produces low lateral pressure at the outlet, the high jet velocity draws the liquid up the capillary tube and into the gas stream, where it is sheared into filaments of liquid that break up into droplets.
151
Q

Residual Volume and Position of SVN

A

Residual volume depends on the position of the SVN. Some SVNs stop producing aerosol when tilted 30 degrees from vertical.

152
Q

Droplet Size and Nebulization and Gas Flow Through the Jet

A

Droplet size and nebulization time are inversely proportional to gas flow through the jet

The higher the flow of gas to the nebulizer, the smaller the particle size generated, and the shorter is the time required for nebulization of the full dose. .

153
Q

Nebulizers that produce smaller particles

A

Nebulizers that produce smaller particle sizes by use of baffles, such as one-way valves, may reduce total drug output per minute compared with the same nebulizer without baffling and require more time or nominal dose to deliver a standard dose of medication to the lungs.

154
Q

The higher the pressure or flow, the _____ the particle size, the _____ the output, and the _____ the treatment time.

A

The higher the pressure or flow, the smaller the particle size, the greater the output, and the shorter the treatment time.

155
Q

Too Low of a Gas Pressure

A

Too low a gas pressure or flow can result in negligible nebulizer output.

156
Q

What Can Happen when a nebulizer is not properly cleaned

A

• Failure to clean the nebulizer properly caused degradation of performance because of clogging of the jet orifice, reducing the output flow, and buildup of electrostatic charge in the device

157
Q

What will gas density effect

A

Gas density affects both aerosol generation and delivery to the lungs.

158
Q

The lower the gas density effect on deposition

A

The lower the density of the carrier gas, the less aerosol impaction as gas passes through the airways, and the greater the deposition of aerosol in the lungs

159
Q

Using Heliox

A

When heliox is used to drive a jet nebulizer at standard flow rates, aerosol output is substantially less than with air or O2, and aerosol particles are considerably smaller.
• When driving a nebulizer with heliox, twofold to threefold greater flow is required to produce a comparable aerosol output.
• Heliox concentrations of 40% or greater have been shown to improve aerosol deposition.37

160
Q

What will humidity and temperature effect

A

• Humidity and temperature can affect particle size and the concentration of drug remaining in the nebulizer.

161
Q

What will evaporation of water and adiabatic expansion of gas do to an aerosol

A

Evaporation of water and adiabatic expansion of gas can reduce the temperature of the aerosol to 10° C less than ambient temperature

This cooling may increase solution viscosity and reduce the nebulizer output, while decreasing particle MMAD.

162
Q

What happends to aerosl particles entrained into a warm and fully saturated gas stream

A

Will increase in size
• These particles also can coalesce (stick together), increasing the MMAD further and, in the case of a DPI, can severely compromise the output of respirable particles.
• How much these particles enlarge depends primarily on the tonicity of the solution.

163
Q

aersol generated in isotonic solutions

A

• Aerosols generated from isotonic solutions probably maintain their size as they enter the respiratory tract.

164
Q

Hypertonic solutions

A

Hypertonic solutions tend to enlarge, whereas evaporation can cause hypotonic droplets to evaporate and shrink.

165
Q

Antibiotics and SVN

A

Some drugs, such as antibiotics, are so viscous that they cannot be used effectively for nebulization in some standard SVNs.

166
Q

Baffle

A

A baffle is a surface on which large particles impact and fall out of suspension, whereas smaller particles remain in suspension, reducing the size of particles remaining in the aerosol.
droplets that impact baffles in the SVN return to the medication reservoir for nebulization again.
Baffles are key elements in nebulizers; well-designed baffling systems decrease both the MMAD (size) and the GSD (range of sizes) of the generated aerosol.
• Atomizers operate with the same basic principles as nebulizers without baffling and produce aerosols with larger MMAD and GSD.

167
Q

Pneumatic (Jet) Nebulizers

A

Most modern jet nebulizers are powered by high-pressure air or oxygen (O2) provided by a portable compressor, compressed gas cylinder, or 50-psi wall outlet.

168
Q

When are Large Volume Jet Nebulizers used

A

• Large volume jet nebulizers can deliver aerosolized drugs to the lung and are particularly useful when traditional dosing strategies are ineffective in the management of severe bronchospasm.

169
Q

Large Volume Jet Nebulizers

A

o These nebulizers have a reservoir greater than 200 ml that produces an aerosol with an MMAD of 2.2 to 3.5 μm.
• Actual output and particle size vary with the pressure and flow at which the nebulizer operates.

170
Q

Concerns with Large Volume Jet Nebulizers

A
  • A concern with continuous bronchodilator therapy (CBT) is increased drug concentration.
  • Patients receiving CBT need close monitoring for signs of drug toxicity (e.g., tachycardia and tremor).
171
Q

Small Particle Aerosol Generator (SPAG)

A

• A large reservoir nebulizer that is pneumatically powered

o Large amount of the solution and very small particle sizes

172
Q

Small Particle Aerosol Generator (SPAG) Solution

A

• Can hold 300 ml of a solution for long periods of nebulization
o These solutions in the reservoir need to be replaced every 24 hours and residual solution should be discarded before adding a new solution

173
Q

What is a Small Particle Aerosol Generator (SPAG) used for

A

• Used for administering ribavirin (antiviral agent) in the treatment of RSV
o There are other ways to treat RSV in infants that may be used.
o Ribavarin with a type of interferon is also used to treat Hep C

174
Q

Small Particle Aerosol Generator (SPAG) Operating Principal

A
  • Operates on jet shearing principle with baffle, also has drying chamber to further reduce particle size to ~1.3 µm MMD
  • Nebulizer connected to hood or ventilator for administration to patient
175
Q

Small Particle Aerosol Generator (SPAG) Design

A
  • It incorporates a drying chamber with its own flow control to produce a stable aerosol.
  • The SPAG reduces medical gas source from the normal 50 pounds per square inch gauge (psig) line pressure to 26 psig with an adjustable regulator.
  • The regulator is connected to two flowmeters that separately control flow to the nebulizer and flow through the drying chamber.
  • The nebulizer is located within the glass medication reservoir, the fluid surface and wall of which serve as primary baffles.
  • As it leaves the medication reservoir, the aerosol enters a long, cylindrical drying chamber.
  • Here the second (separate) flow of dry gas is added, reducing particle size by evaporation, creating a monodisperse aerosol with an MMAD of 1.2 to 1.4 μm.
  • Nebulizer flow should be maintained at approximately 7 L/min with total flow from both flowmeters not less than 15 L/min.
  • The latest model operates consistently even with back pressure and can be used with masks, hoods, tents, or ventilator circuits.
176
Q

Small Particle Aerosol Generator (SPAG) Concerns

A
  • Two specific problems are associated with SPAG use to deliver ribavirin.
  • The first is caregiver exposure to the drug aerosol
  • The other problem occurs only when the SPAG is used to deliver ribavirin through a mechanical ventilator circuit.
  • Drug precipitation can jam breathing valves or occlude the ventilator circuit. This problem can be overcome by (1) placing a one-way valve between the SPAG and the circuit and (2) filtering out the excess aerosol particles before they reach the exhalation valve, and changing filters frequently to avoid increasing expiratory resistance.44
177
Q

What are Hand-bulb atomizers and nasal spray pumps are used for

A

administer sympathomimetic, anticholinergic, antiinflammatory, and anesthetic aerosols to the upper airway, including nasal pas- sages, pharynx, and larynx
• These agents are used to manage upper airway inflammation and rhinitis, to provide local anesthesia, and to achieve systemic effects.

178
Q

How do Spray Pumps Work

A

Will generate relatively low pressure and does not have baffles, it produces an aerosol with large particle size (high MMAD and GSD), ideal for upper airway deposition.

Deposition with the hand-bulb atomizer applied to the nose occurs mostly in the anterior nasal passages with clearance to the nasopharynx.
The 100-mcl puffs appear to deposit more medication than 50-mcl puffs, and deposition to a greater surface area occurs with a 35-degree spray angle than with a 60-degree angle.

179
Q

MDI Populatrity

A

• MDI are the most common medication aerosol medication device as when they are properly used they are at least as effect as other drug nebulizers for drug delivery
o For this reason, pMDIs often are the preferred method for delivering bronchodilators to spontaneously breathing patients and patients who are intubated and undergoing mechanical ventilation

180
Q

What is a MDI

A

A small pressurized canister that contains a prescription drug (a micronized powder or aqueous solution) in a volatile propellant combined with a surfactant and dispersing agent

181
Q

MMAD for MDI

A

2- 6 µm MMAD
the initial velocity and dispersion of the aerosol plume generate larger particles that decrease in size as they leave the pMDI, resulting in approximately 80% of the dose leaving the actuator to impact and become deposited in the oropharynx.

182
Q

How to tell if the MDI is empty

A

It seems light-You can hold the canister next to your ear and shake it several times. If it has medicine, you’ll hear and feel the liquid contents swishing back and forth.

There is no movement of particles

The counter is at 0

183
Q

Deposition from an MDI

A

• Due to the initial velocity and dispersion of an aerosol 80% of a dose leaving the actuator will impact and deposition in the oropharynx
o Pulmonary deposition ranges from 10-20%

184
Q

Propellants in MDIs

A

Hydrofluoroalkane (HFA)-134a is a environment-friendly and clinically safe propellant

In addition to the propellant, pMDIs use dispersal agents to improve drug delivery by keeping the drug in suspension.
The most common dispersal agents are surfactants, such as soy lecithin, sorbitan trioleate, and oleic acid.

These agents help keep the drug suspended in the propellant and lubricate the valve mechanism but may also cause adverse responses (coughing or wheezing) in some patients.

185
Q

MDI Technique

A
  • When the canister is inverted (nozzle down) and placed in its actuator, or “boot,” the volatile suspension fills a metering chamber that controls the amount of drug delivered.
  • Pressing down on the canister aligns a hole in the metering valve with the metering chamber
  • The high propellant vapor pressure quickly forces the metered dose out through this hole and through the actuator nozzle.
  • As the liquid suspension is forced out of the pMDI, it forms a plume, within which the propellants vaporize. Initially, the velocity of this plume is high (approximately 15 m/sec).
  • The output volume of pMDIs ranges from 30 to 100 mcl.
186
Q

Priming an MDI

A
  • Every pMDI should be primed by shaking and actuating the device to atmosphere one to four times (see label for the specific device) before initial use and after storage.
  • Without priming, the initial dose actuated from a new pMDI canister contains less active substance than subsequent actuations.
187
Q

Loss of dose from a MDI

A
  • This “loss of dose” from a pMDI occurs when drug particles rise to the top of the canister over time (“cream”).
  • A reduction in emitted dose with the first actuation commonly occurs with a pMDI after storage, particularly with the valve pointed in the downward position.
  • Loss of prime is related to valve design and occurs when propellant leaks out of the metering chamber during periods of nonuse (e.g., 4 hours).
  • The result is reduced pressure and drug released with the next actuation.23
  • Improved designs of metering valves developed for use with HFA propellants reduce these losses.
188
Q

cold Freon effect

A

• Some patients exhibit a “cold Freon effect,” which occurs when the cold aerosol plume reaches the back of the mouth and the patient stops inhaling. All of these problems reduce aerosol delivery to the lung to the point that the patient does not benefit from the medication, but they can be corrected entirely or in part by use of the proper pMDI accessory device.

189
Q

anticholinergic Agents and Gluocoma

A

• Use of anticholinergic agents has been associated with increased ocular pressure, which could be dangerous for patients with glaucoma. For avoidance of ocular exposure, the drug manufacturer recommends patients use the closed-mouth technique with ipratropium.

190
Q

Optimal Technique for Use of a MDI

A
  1. Warm the pMDI to hand or body temperature and shake it vigorously
  2. Before use of a new pMDI and when the pMDI has not been used for several days prime the pMDI by pointing it into the air (away from people) and actuating a couple of times
  3. Assemble the apparatus and uncap the mouthpiece assuring there are no losse objects in the device
  4. Open mouth technique. Open you mouth wide, keeping tongue down Hold the pMDI with the canister oriented donward and the outlet aimed at yout mouth. Position the pMDI ~4cm (2 finger breaths) away from your mouth
  5. Closed mouth technique. Place mouthpiece between lips with tongue out of the path of the outlet
  6. Breathe out normally
  7. As you slowly begin to breath in (<0.5 L/sec) actuate the pMDI
  8. Continue inspiration to total lung capacity
  9. Hodl your breath for up to 10 seconds. Then relax, and breath normally
  10. Wait 1 minute between puffs
  11. Dissassemble the apparatus and recap the mouthpiece
191
Q

Parts of an MDI

A
o	Drug
o	Propellant
o	Canister
o	Metering valve
o	Actuator with mouthpiece
192
Q

MDI Mechanism of Action

A

• When inverted an placed in a actuator the suspension will fill the metering valve chamber
• Then the canister is depressed into the actuator the drug/propellant mixture in the metering valve will be release under pressure
• The liquid propellant is ejected from the pressurized valve and will rapidly expand and vaporizes (ambient pressure)
o Shatters liquid stream into an aerosol
o Pressure in canister is specific to medication formulation
• Upon release, metering valve refills with drug- propellant mixture from canister and is ready for next discharge

193
Q

Factors Affecting MDI Performance-Temperature

A
  • Low temperature (<10° C) decreases the output of CFC pMDIs.
  • Patients with cold air–induced bronchospasm who keep their pMDIs in outer coat pockets when outside in cold winter weather may receive only a small percentage of drug compared with that administered with the same pMDI at 25° C.
  • This problem has been less serious with the newer HFA pMDIs.
194
Q

Factors Affecting MDI Performance-Timing of Actuation Intervals

A

• Rapid actuations can lead to turbulence and coalescence of particles
o Actuations – at least 30 seconds apart

195
Q

Factors Affecting MDI Performance-Drug Concentration

A

Changes in drug concentration concentration in first discharge, if standing unused
o Drug suspension can separate from propellant when stored unused (creaming)

196
Q

Factors Affecting MDI Performance-Loss of Propellant

A

o Little or no drug discharged on actuation
o Can be felt and heard by user
o Usually takes days and weeks to occur
o Regular use of MDI prevents this!

197
Q

Factors Affecting MDI Performance-Particle Size

A

The particle size of aerosolized drug released controlled by:
Vapor pressure of propellant blend- Increased vapor pressure will decrease particle size
Diameter of actuator opening-Decreased actuator opening will decrease particle size

198
Q

Factors Affecting MDI Performance-Nozzle Size and Cleanliness

A
  • Aerosol drug delivery is influenced by nozzle size and cleanliness.
  • Nozzle size is pMDI- specific.
  • As debris builds up on the nozzle or actuator orifice, the emitted dose is reduced.24
  • Manufacturer recommendations should be followed for cleaning. pMDI canisters should never be placed under water
199
Q

Factors Affecting MDI Performance-Priming

A
  • Priming is defined as shaking the device and releasing one or more sprays into the air when the pMDI is new or has not been used for awhile.
  • It is done to mix the drug and the propellant, which can separate in the canister over time. Priming is required to provide an adequate dose, according to the manufacturer’s guidelines.
200
Q

Disadvantages of MDI

A

hand- breathing coordination required (if no holding chamber used)
• Canister depletion difficult to determine accurately
• Possible reactions to propellant
• High oropharyngeal impaction and loss if holding chamber not used
• Foreign body aspiration of coins and debris from mouth piece

o

201
Q

MDI Reservoir Devices

A

• Simple extension devices that puts distance between MDI and patient’s mouth

Were designed to simplify the complex coordination of aiming, actuation and breathing with an MDI.
• MDI accessory devices designed to decrease initial velocity of particles released from MDI before reaching oropharynx
decrease oropharyngeal deposition

202
Q

• Function of the reservoir device is to add distance between the MDI and the mouth which will:

A

o Which will reduce the initial forward velocity of the pMDI droplets, which occurs with partial evaporation of propellant in the time the aerosol traverses the length of the spacer.
 The reduction in initial forward velocity decreases the number of nonrespirable particles reaching the airway.
 The increase of space and time will also allow for a decrease in size through vaporization of the propellant and evaporation of the initial large particle sizes
• The MMAD of the aerosol emitted from the pMDI exiting a spacer decreases approximately 25%, whereas the fraction containing particles less than 5 μm in diameter increases.
o Will also simplify the coordination for the user

203
Q

• Multiple actuations of one or more drugs into a spacer

A

• Multiple actuations of one or more drugs into a spacer reduce both the total dose and the respirable dose of drug available for inhalation as respirable particles containing drugs will settle out and become deposited within the device cause a whitish buildup on the inner chamber walls.
o The extent of these losses may vary for different drugs and spacer designs.23
o This residual drug poses no risk to the patient but should be be rinsed out periodically.

204
Q

Spacers with Electrostatic charge

A

• Plastic spacers decrease drug output due to the presence of an electrostatic charge. With these devices, a buildup of material can be seen on the walls of the chamber.
o As more material builds up on the wall of the chamber, the charge is dissipated, and more drug is inhaled by the patient.
o Washing the chamber with water (without soap) causes the electrostatic charge to be reestablished, making the device less effective for the next few puffs, until the static charge in the chamber (which attracts small particles) is again reduced.32
o Use of conductive metal or nonelectrostatic plastic chambers or washing the plastic chamber periodically with deionizing detergent (liquid dishwashing soap) can overcome the loss of fine-particle mass owing to electrostatic charge and increase the inhaled mass from 20% to 50% of the emitted dose of the pMDI, even in children
o The effect of washing the chamber with conventional dishwashing soap reduces this static charge for up to 30 days.
o All manufacturers recommend that VHCs and spacers should be cleaned regularly, typically monthly using dilute liquid dishwashing soap, with or without rinsing, and allowing them to air dry.

205
Q

Spacers with a mask

A

• VHCs with masks are available for use in the care of infants, children, and adults. These units allow effective administration of aerosol from a pMDI to patients who are unable to use a mouthpiece device (because of their size, age, coordination, or mentation)
o Exhalation valves in a face mask attached to a spacer device must also provide low resistance. Issues of spacer volume, VT, frequency of breathing, and mechanical dead space between the spacer and mouth are of particular concern when these devices are used by children.32

206
Q

• Basic concepts for spacer devices

A

o Small volume adapters
o Open tube designs
o Bag reservoirs
o Valved holding chambers

207
Q

• Reservoir device or extension device

A

o Global term for spacers and holding chambers

208
Q

• Spacers

A

o Simple valve-less extension device
o Extend the distance from the aerosol spray away from mouth
 This distance allows the aerosol plume to expand and the propellants to evaporate before the medication reaches the oropharynx.
 The larger particles will impact on the walls of the spacer
 This will reduce oropharyngeal impaction and increase pulmonary deposition
o Proper use of a simple open-tube spacer still requires some hand-breath coordination because a momentary delay between triggering and inhaling the discharged spray results in a substantial loss of drug and reduced lung delivery.
o Exhalation into a simple spacer after pMDI actuation clears the aerosol from the device and wastes most of the dose to the atmosphere. This reduction in dose also occurs with small volume reverse-flow design spacers if there is no provision for “holding” the aerosol in the device.29

209
Q

• Holding chamber

A

o A spacer device with addition of one way valves
• The one way valve must be able to withstand the initial pressure from the pMDI when the device is triggered to retain aerosol and have sufficiently low resistance to open readily when the user inhales, in particular, when the user is a child or an infant.
o Contain and hold aerosol until inspiration occurs
o This allows patients with a small VT to empty the aerosol from the chamber over two or more successive breaths.
o Provides less oropharyngeal deposition, higher respirable drug dosages, and better protection from poor hand-breath coordination than simple spacers.
o VHCs protect the patient from poor hand-breath coordination, with exhaled gas venting to the atmosphere, allowing aerosol to remain in the chamber available to be inhaled with the next breath. VHCs allow infants, small children, and adults who cannot control their breathing pattern to be treated effectively with pMDIs.
o A simple tube spacer may reduce oral deposition by 90%, whereas a valved holding chamber can reduce oral deposition by 99%.
o The placement of a valve between the pMDI, the chamber, and the mouthpiece works like a baffle reducing the size of particles inhaled.

210
Q

Optimal Use of a MDI with a Valved Holding Chamber

A
  1. Warm the pMDI to hand or body temperature and shake it vigorously
  2. Before use of a new pMDI and when the pMDI has not been used for several days prime the pMDI by pointing it into the air (away from people) and actuating a couple of times
  3. Assemble the apparatus and uncap the mouthpiece assuring there are no losse objects in the device
  4. Place pMDI in holding chamberinlet, position the chamber outlet in the mouth or place the mask over the nose and mouth and encourage the patient to breath through their mouth while visually inspecting for valve function
  5. With normal breathing actuate the pMDI once and have the patient breathe through the device for 3-7 breaths (3 breaths for adults and 7 for infants)
  6. Allow 30-60 seconds between actutation

*With a cooperative patient synchronizing actuation at the beginning of a larger breath with breath holding may be encouraged. However, the maneuter has not been shon to increase lcinical response to inhaled bronchodilators

211
Q

tail-off effect

A

After the number of label doses has been administered, the pMDI may seem to give another 20 to 60 doses, which may deliver little or no medications as the doses “tail-off.”

The tail-off effect refers to variability in the amount of drug dispensed toward the end of the life of the canister.

The result of tail-off is swings from normal to almost no dose emitted from one breath to the next with no reliable indicator to the user.

212
Q

DPI

A

• These devices are breath-actuated (do not require a propellant), with turbulent air flow from the inspiratory effort of the user providing the power to create an aerosol of the fine particles of drug
o Self-generated flows of between 30 – 90 lpm are needed for drug deposition
• Flow from user creates an aerosol of microfine solid particles of drug as it is inhaled through mouth piece
• Are as effective as MDIs for deposition & drug response.

213
Q

Common DPI Designs

A

Diskus
Turbuhaler
HandiHaler

214
Q

DPI and Carrier Substances

A

Most passive DPIs require the use of a carrier substance (lactose or glucose) mixed into the drug to enable the drug powder to deaggregate more readily and flow out of the device

Reactions to lactose or glucose are fewer than reactions to the surfactants and propellants in MDIs, but the amount of these substances is substantially greater than the amount of the drug

The particle size of the dry powder particles of drug ranges from 1 to 3 μm. However, the size of the lactose or glucose particles can range from approximately 20 to 65 μm, so most of the carrier (≤80%) is deposited in the oropharynx.

215
Q

Types of DPIs

A

Unit-dose DPI
Multiple unit-dose DPI
Multiple dose drug reservoir DPI.

216
Q

Factors Affecting DPI Performance and Drug Delivery-Intrinsic Resistance and Inspiratory Flow Rate

A
  • Optimal performance for each DPI design occurs at a specific inspiratory flow rate.
  • The higher the resistance or the greater the flow requirement of a DPI device, the more difficult it is for a compromised or young patient to generate inspiratory flow sufficient to obtain the maximum dose of drug from the device.

If a patient does not inhale at the optimal inspiratory flow rate for a particular device, delivery to the lung decreases as the dose of drug dispensed decreases and the particle size of the powder aerosol increases

217
Q

Factors Affecting DPI Performance and Drug Delivery-Exposure to Humidity and Moisture

A
  • The emitted dose of DPI decreases in a humid environment, likely because of powder clumping.
  • The longer the exposure and the greater the level of absolute humidity, the lower the dose emitted.
218
Q

Passive vs Active DPI

A

Passive, or patient-driven, DPIs rely on the patient’s inspiratory effort to dispense the dose. The result is differences in lung delivery and clinical response.

Active or powered DPI devices, which deaggregate the powder before inhalation, are independent of patient effort. Active DPIs use an energy source to deaggregate the powder and suspend the powder into an aerosol, allowing the dose to be suspended independent of patient inspiratory flow rates.

219
Q

Appropriate Patient Population for Passive DPIs

A

Because infants, small children (<5 years old) and patients who are unable to follow instructions cannot develop inspiratory flows his high, these patients cannot use DPIs.

Because patients with severe airway obstruction may be unable to achieve the required flow, they should not use DPIs during acute bronchospasm.

220
Q

Exhalation into a DPI before inspiration

A

Exhalation into a DPI before inspiration can result in loss of drug delivery to the lung.

221
Q

DPI Cleaning

A

Although the DPI may require cleaning in accordance with the product label, the device should never be submerged in water. Moisture in the device dramatically reduces available dose.

222
Q

inspiratory flow rate for DPI

A

• The most critical factor in using a passive DPI is the need for high inspiratory flow.
o Patients must generate an inspiratory flow rate of at least 40 to 60 L/min to produce a respirable powder aerosol.

223
Q

Ellipta®

A

disposable multidose DPI in which the drug is stored in double-foil blister strips.
• The device has a 3-step technique (open-inhale-close) and provides auditory feedback with the opening of the inhaler that results in loading the dose and an advancement in the dose counter.
• When a patient does not inhale the dose from the Ellipta®, the drug is dumped internally to prevent overdosing.

224
Q

The Ellipta® has three categories that provide different drugs or drug combinations:

A

Incruse Ellipta® delivers umeclidinium, a long-acting muscarinic antagonist that is used in the treatment of COPD
o BreoTM Ellipta® has a combination of fluticasone furoate and vilanterol (long- acting β2-agonist)
o AnoroTM Ellipta® includes a combination of umeclidinium and vilanterol.

225
Q

Diskus

A
  • Pre- loaded doses
  • Each dose contained in foil blister which is advanced and opened as inhaler is used
  • The doses are contained in 60 sealed pockets alone the aluminum foil strip that is advanced along the lever
  • As the drug pocket reaches the mouthpiece the cover is peeled away making the drug available for inhalation
  • There is a dose counter indicating the number of doses remianing
226
Q

Turbuhaler

A
•	Powder preparation preloaded in device
o	Opened by rotating grip or thumb wheel
•	High number of doses
o	60 to 200
•	May have a counter incorporated or gives a warning indication when there are ~20 doses left
•	Effective at flow rates ~ 40 lpm 30-60
•	Desiccating agent present
227
Q

Handihaler

A
  • Contains single- dose powder preparation of drug in gelatin capsule
  • Capsule inserted into device & punctured to release powder prior to inhalation
  • Carrier substance (glucose or lactose) improves flow properties of powder mixture and provides suitable volume to unit dose
228
Q

Advantages of DPI

A
  • Small and portable
  • Short preparation and administration time
  • Less hand- breathing coordination
  • No propellants (thus environmentally friendly)
  • No ‘cold freon effect’ causing bronchoconstriction or inhibiting full inspiration
  • Count of remaining drug doses relatively easy
  • No extension device needed
229
Q

Disadvantages Of DPI

A
  • Patients not as aware of dose inhaled thus may distrust delivery
  • Possible reaction to glucose or lactose carrier substance
  • High inspiratory flow rates needed
  • Most of carrier impacts in oropharynx & can cause irritation
230
Q

• Equipotent dose:

A

The dose by each delivery method that produces an equivalent degree of therapeutic effect

231
Q

• Ratio of SVN to MDI

A

~ 1:2
2.5 mg SVN=5 puff MDI
250 mg SVN=4 puff MDI

232
Q

Systemic Vs. inhalation/Instillation

A
  • IV Indications – giving certain agents systemically vs inhaled or instilled for direct systemic effect, more immediate response (rapid tissue dispersal)
  • Systemic drug delivery is effective for agents being used for systemic effect: i.e.: using a vasopressor to increase blood pressure.
  • Agents that are to be used for lung effect are most often given via inhalation for efficiency without systemic side effects.
233
Q

Factors Associated With Reduced Aerosol Drug Deposition In The Lung

A
  • Mechanical ventilation
  • Artificial airways
  • Reduced airway size (infants and children)
  • Severe airway obstruction
  • Poor patient compliance and Technique
  • Limitation of specific delivery device
  • Exhalation into device can result in loss of drug
234
Q

indications for MDI

A
  • Able to follow instructions / demonstrate correct use
  • Adequate inspiratory capacity
  • Capable of breath hold
  • Stable respiratory pattern
  • Drug available in MDI form
235
Q

Indications fo DPI

A

• Drug available in DPI form
• Poor MDI coordination
• Sensitive to propellants
• Capable of generating high inspiratory flow rates (> 30-60 lpm) depending on drug
o High inspiratory flow is the most critical factor for DPI
o Should not be used with patients unable to generate high flows such as small children and patients with acute bronchospasm
• Need accurate dose count monitoring
• Strive for consistency with devices.
• High humidity can affect DPI drug availability
o Hygroscopic particles will clump together when exposed to high humidity increasing particle size

236
Q

Aerosol Therapy for Treatment of Pulmonary Arterial Hypertension

A

Epoprostenol (Veletri®), epoprostenol sodium (Flolan®), iloprost (Ventavis®), and treprostinil (Tyvaso) are inhaled prostacyclins used for treatment of pulmonary arterial hypertension.

Epoprostenol administration is associated with positive effects on symptoms, hemodynamics, exercise capacity, disease progression and survival,it has not been approved for inhalation, and due to its short half-life of 30 to 90 seconds, requires continuous nebulization.

In contrast, iloprost and treprostinil are approved for inhalation with a half-life of 60 to 90 minutes, allowing more convenient dosing to ambulatory patients.

237
Q

• Four primary forms of aerosol generator are used to deliver aerosols during mechanical ventilation:

A

o SVN, USN, VM nebulizer, and pMDI with third-party adapter.

238
Q

Aerosol Administration to Mechanically Ventilated Patients

Doses

A

Will be similar to non-intubated patients

239
Q

What is aging when pertaining to aerosols?

A

The process by which the aerosol suspension changes over time.

240
Q

What is a Metered-dose inhaler (MDI)?

A

A pressurized canister containing the prescribed drug in a volatile propellant combined with surfactant and a dispersing agent.

241
Q

What is a positive response indicated from Continuous nebulization?

A

An increase in peak flow of greater than 10% with a goal of at least 50%.

242
Q

What is a technical downfall of MDIs?

A

80% of the aerosol hits the back of the throat depositing the medication in the oropharynx.

243
Q

What is an ultrasonic nebulizer capable of?

A

Higher aerosols outputs and higher aerosol densities than conventional jet nebulizers.

244
Q

What is the most commonly prescribed method of aerosol therapy?

A

MDI

245
Q

What is the primary hazard of aerosol drug therapy?

A

An adverse reaction to the medication.

246
Q

What is the relationship between GSD and the range of particle sizes?

A

The greater the GSD, the wider the range of particle sizes and therefore a more dispersed aerosol.

247
Q

What’s the difference between spacers and holding chambers?

A

A spacer is valve-less and just adds distance from the point of discharge to the mouth. A holding chamber has valves for holding the medication.

248
Q

Where should the aerosol generator be placed with IPPV?

A

In the circuit close to the patient’s airway.

249
Q

Why would you prime an MDI?

A

To mix the drug and propellant and to ensure that an adequate dose is provided.

250
Q

Why would you use continuous nebulization?

A

For treatment of refractory bronchospasm. Nebulized albuterol is dosed at 5-20mg/hour.

251
Q

What are the three categories of DPIs?

A

(1) Unit-Dose DPI, (2) Multiple unit-dose DPI, and (3) Multiple Dose Drug Reservoir DPI.

252
Q

Aerosol particles can change size as a result of what?

A

Evaporation or hygroscopic water absorption

253
Q

What is aerosol aging?

A

The process by which an aerosol suspension changes over time

254
Q

What is the SPAG?

A

The SPAG was manufactured by ICN Pharmaceuticals specifically for administration of ribavirin (Virazole) to infants with respiratory syncytial virus infection. It incorporates a drying chamber with its own flow control to produce a stable aerosol.

255
Q

What is the baffle?

A

A surface on which large particles impact and fall out of suspension, whereas smaller particles remain in suspension, reducing the size of particles remaining in the aerosol.

256
Q

Before initial use and after storage, every pMDI should be what?

A

They should be primed by shaking and actuating the device to atmosphere one to four times. Without the priming, the initial dose actuated from a new pMDI canister contains less active substance than subsequent actuations. You should waste a single does when it has not been used for 4-6 hours.

257
Q

What are breath-actuated nebulizers?

A

An aerosol device that is responsive to the patient’s inspiratory effort and reduces or eliminates aerosol generation during exhalation. They can generate aerosol only during inspiration. This eliminates the waste of aerosol during exhalation and increases the delivered dose threefold or more over continuous and breath-enhanced nebulizers.

258
Q

What is a Breath-Actuated Pressurized Metered Dose Inhaler?

A

A variation of a pMDI that incorporates a trigger that is activated during inhalation. This trigger reduces the need for the patient or caregiver to coordinate MDI actuation with inhalation.

259
Q

What are Breath-Enhanced Nebulizers?

A

They are nebulizers that entrain room air in direct relationship to the inspiratory flow of the patient. They generate aerosol continuously, using a system of vents and one-way valves to minimize aerosol waste.

260
Q

The CDC recommends that nebulizers should be what?

A

They should be cleaned and disinfected, or rinsed with sterile water, and air-dried between uses.

261
Q

What are Chlorofluorocarbons (CFCs)?

A

They are gaseous chemical compounds that were originally used to power metered dose inhalers but have been phased out of use.

262
Q

What is the process of cleaning holding chambers and spacers?

A

They should be cleaned regularly, typically monthly, as recommended by the manufacturer. Use of dilute liquid dishwashing soap, with or without rinsing, and allowing to air dry are recommended.

263
Q

Clinical efficacy varies according to what?

A

It varies according to both patient technique and device design. For these reasons, the best approach to aerosol drug therapy is to use an assessment-based protocol that emphasizes individually tailored therapy modified according to patient response.

264
Q

Cold air and high-density aerosols can cause what?

A

Reactive bronchospasm and increased airway resistance.

265
Q

What are the concerns in the use of disposable nebulizers with compressors at home?

A

Possible degradation of the performance of the plastic device over multiple uses

266
Q

DPIs should not be used for what?

A

They should not be used for the management of acute bronchospasm.

267
Q

Droplet size and nebulization time are inversely proportional to gas flow through the jet?

A

The higher the flow of gas to the nebulizer, the smaller the particle size generated, and the shorter is the time required for nebulization of the full dose.

268
Q

Drugs for nebulization that escape from the nebulizer into the atmosphere or are exhaled by the patient can be inhaled by who?

A

They can be inhaled by anyone in the vicinity of the treatment. The risk imposed by this environmental exposure is clear and is associated with a range of drugs and patients with infectious disease. Pentamidine and ribavirin were associated with health risks to health care providers even when used in conjunction with filters on exhalation ports of nebulizers, containment and scavenger systems, and high-efficiency particulate air (HEPA) filter hoods and ventilation systems.

269
Q

What is a Dry Powder Inhaler (DPI)?

A

Typically a breath-actuated dosing system. The patient creates the aerosol by drawing air though a dose of finely milled drug powder with sufficient force to disperse and suspend the powder in the air. The dispersion of the powder into respirable particles depends on the creation of turbulent flow in the inhaler.

270
Q

Exhalation into the device before inspiration can result in what?

A

It can result in the loss of drug delivery to the lungs.

271
Q

Eye irritation is caused by what?

A

An aerosol administered via face mask which causes the drug to be deposited in the eyes.

272
Q

What is a pMDI?

A

It is a pressurized canister that contains the prescribed drug in a volatile propellant combined with a surfactant and dispersing agent. It is used to administer bronchodilators, anticholinergics, and steroids. They are easy to use but are commonly misused.

273
Q

Poor patient response to bronchodilator therapy often occurs because what?

A

An inadequate amount of drug reaches the airway. To determine the “best” dose for patients with moderate obstruction, the respiratory therapist should conduct a dose-response titration.

274
Q

What is a potential problem with continuous bronchodilator therapy (CBT)?

A

An increase in drug concentration can be adversely given. Patients receiving CBT needs close monitoring for signs of drug toxicity (e.g., tachycardia and tremor)

The precise amount of drugs delivered to the patient’s airways

275
Q

The precise amount of drugs delivered to the patient’s airways can be measured in terms of what?

A

The patient’s clinical response to aerosol drug therapy including the desired therapeutic effects and any unwanted adverse effects.

276
Q

What procedures are used to help reduce contamination and infection associated with respiratory care equipment?

A

Nebulizers should be sterilized between patients, nebulizers should frequently be replaced with disinfected or sterile units or rinsed with sterile water (not tap water) and air dried every 24 hours.

277
Q

What is residual drug volume?

A

Also known as dead volume, it is the medication that remains in the SVN after the device stops generating aerosol and “runs dry.” The residual volume of a 3-ml dose can range from 0.5 to more than 2.2 ml, which can be more than two-thirds of the total dose. Residual volume also depends on the position of the SVN.

278
Q

Restlessness, diaphoresis, and tachycardia also may indicate what?

A

Severity of airway obstruction but must not be confused with bronchodilator overdose.

279
Q

A simple albuterol dose-response titration involves what?

A

It involves giving an initial 4 puffs (90 mcg/puff) at 1-minute intervals through a pMDI with a holding chamber. After 5 minutes, if airway obstruction is not relieved, the respiratory therapist gives 1 puff per minute until symptoms are relieved, heart rate increases to more than 20 beats/min, tremors increase, or 12 puffs are delivered. The best dose is the dose that provides maximum relief of symptoms and the highest PEFR without side effects.

280
Q

What are Small volume nebulizers (SVNs)?

A

They are most commonly used for medical aerosol therapy and hold 5 to 20 ml of medication.

281
Q

Small volume USNs have been promoted for administration of a wide variety of formulations ranging from what?

A

Bronchodilators to anti-inflammatory agents and antibiotics.

282
Q

Sole dependence on tests of expiratory airflow for assessing patient response to therapy is?

A

It is unwise because not all patients can perform these maneuvers. Other components of patient assessment useful in evaluating bronchodilator therapy include patient interviewing and observation, measurement of vital signs, auscultation, blood gas analysis, and oximetry.

283
Q

What is a spacer?

A

A spacer is a simple valve-less extension device that adds distance between the MDI outlet and the patient’s mouth. This distance allows the aerosol plume to expand and the propellants to evaporate before the medication reaches the oropharynx.

284
Q

Spacers and valved holding chambers are what?

A

They are MDI accessory devices designed to reduce both oropharyngeal deposition and the need for hand-breath coordination. All spacers add distance between the MDI and the mouth, reducing the initial forward velocity of the MDI droplets. It also helps to reduce foul taste of the medication.

285
Q

Spontaneous breathing in all patients, including pediatric and neonatal patients, results in what?

A

It results in greater deposition of aerosol from an SVN than occurs with positive pressure breaths (e.g., intermittent positive pressure ventilation). This mode of ventilation reduces aerosol deposition more than 30% compared with the effect of spontaneously inhaled aerosols.

286
Q

What is the technique for using an SVN?

A

Slow inspiratory flow optimizes SVN aerosol deposition. Deep breathing and breath holding during SVN therapy do little to enhance deposition over normal tidal breathing. As long as the patient is mouth breathing, there is little difference in clinical response between therapy given by mouthpiece and therapy given by mask.

287
Q

What are the three categories of nebulizers?

A

(1) Pneumatic jet nebulizers, (2) USNs, and (3) VM nebulizers.

288
Q

What is the recommended timing of actuation intervals?

A

Manufacturers recommended 30 seconds to 1 minute between actuations. Very rapid actuations of multiple puffs per breath reduces inhaled drug per puff.

289
Q

In order to avoid an opportunistic oral yeast infection, the patient should do what?

A

They should rinse the mouth after steroid use.

290
Q

What are two specific problems that are associated with SPAG use to deliver ribavirin?

A

(1) Caregiver exposure to the drug aerosol, and (2) Drug precipitation can jam breathing valves or occlude the ventilator circuit.

291
Q

A typical SVN is powered by what?

A

It is powered by a high-pressure stream of gas directed through a restricted orifice (the jet). The gas stream leaving the jet passes by the opening of a capillary tube immersed in solution. Because it produces low lateral pressure at the outlet, the high jet velocity draws the liquid up the capillary tube and into the gas stream, where it is sheared into filaments of liquid that break up into droplets.

292
Q

What are unit-dose DPIs?

A

They dispense individual doses of the drug from punctured gelatin capsules.

293
Q

The USN uses a piezoelectric crystal to do what?

A

To generate an aerosol. The crystal transducer converts an electrical signal into high-frequency (1.2- to 2.4-MHz) acoustic vibrations. These vibrations are focused in the liquid above the transducer, where they disrupt the surface and create oscillation waves. If the frequency of the signal is high enough and its amplitude strong enough, the oscillation waves form a standing wave that generates a geyser of droplets that break free as fine aerosol particles.

294
Q

Valved holding chambers are used for what?

A

They are used to protect the patient from poor hand-breath coordination, with exhaled gas venting to the atmosphere, allowing aerosol to remain in the chamber available to be inhaled with the next breath. They allow infants, small children, and adults who cannot control their breathing pattern to be treated effectively with MDIs.

295
Q

What is Volume Mean Diameter (VMD)?

A

The median diameter of an aerosol particle measured in units of volume.

296
Q

Well-designed baffling systems decrease what?

A

They decrease both the MMAD (size) and the GSD (range of sizes) of the generated aerosol.

297
Q

When ribavirin or pentamidine is given, the treatment is provided where?

A

It is provided in a private room. The room should be equipped for negative pressure ventilation with adequate air exchanges (at least six per hour) to clear the room of residual aerosols before the next treatment. HEPA filters should be used to filter room or tent exhaust, or the aerosol should be scavenged to the outside.

298
Q

When used in conjunction with high-frequency oscillatory ventilation, administration of albuterol sulfate via a VM nebulizer placed between the ventilator circuit and the patient airway has been reported to what?

A

To deliver greater than 10% of the dose to both infants and adults. A pMDI with an adapter placed immediately proximal to the endotracheal tube achieved similar results in adult patients ventilated via high-frequency oscillatory ventilation.

299
Q

With continuous or bias flow through the ventilator circuit, the delivery is reduced how?

A

It is reduced as the flow increases, whereas placement of a VM nebulizer near the ventilator increases delivery.

300
Q

Without a dose counter, there is no viable method to determine what?

A

To determine the remaining drug in a MDI other than manually keeping a log of every dose taken.

301
Q

What are some of the advantages of using an MDI?

A

They are inexpensive, light, compact, resistant to moisture, They provide a quick delivery of drugs, as well as precise and consistent doses. They are available with most anti-asthmatic drugs.

302
Q

What are some of the disadvantages of an MDI?

A

Some patients have difficulty in the coordination of activation and inspiration. It can be time-consuming to teach. There is also the cold-freon effect, which is the inability to continue to breathe when the propellant is released into mouth.

303
Q

What patients cannot use a DPI?

A

Children under the age of 5 and patients unable to generate a high air flow. They also may not work as well in high humidity environments.

304
Q

When should an MDI be activated for a ventilator patient?

A

Coordinate firing the MDI with the beginning of the ventilator inspiration.

305
Q

How does an atomizer differ from an SVN?

A

Atomizers don’t have baffles. They are usually powered by a hand-squeezed bulb. Because the particles are larger, the drug deposits in the upper airway. You might deliver a local anesthetic through an atomizer prior to bronchoscopy.

306
Q

DPIs require a high inspiration flow of what?

A

60 L/minute

307
Q

What are some of the Advantages of a spacer?

A

No need to activate coordination with inspiration, Increases drug deposition in the lungs, Reduces drug deposition in the mouth, Can be used in children with a face mask, and Decreases the incidence of oral thrush.

308
Q

What are some of the characteristics of Jet Nebulizer?

A

Cools during operation, provides a small aerosol particle size, and is less expensive.

309
Q

In what part of the lung would you like to deposit beta-adrenergic bronchodilator drugs?

A

In the lower airways.

310
Q

SVN dosages should be adjusted when delivered to an intubated patient by what amount?

A

Give 2 to 5 times the normal dose.

311
Q

What is the optimal flow rate and amount of solution to put in an SVN?

A

6 to 8 L/minute.

312
Q

What are of the characteristics of ultrasound nebulizers?

A

Heats up during operation, Larger aerosol particles, More expensive, and Less noise.

313
Q

What class of inhaled drugs requires that you always use a spacer or chamber?

A

Corticosteroids to reduce oropharyngeal deposition.

314
Q

What is the aerosol output an ultra sound nebulizer is capable of delivering?

A

0.2 to 1.0 ml/minute

315
Q

What are some of the hazards of aerosol therapy?

A

Bronchospasm, Over-hydration, Overheating of inspired gases, Delivery of contaminated aerosol, and Tubing condensation draining into the airway.

316
Q

What devices generate therapeutic aerosols?

A

Atomizers and Nebulizers.

317
Q

Where do most aerosol particles in the 5-10 um range deposit?

A

Upper airways.

318
Q

Where do most aerosol particles in the 1-5 um range deposit?

A

Central airways.

319
Q

What term describes the primary mechanism for deposition of small particles?

A

Brownian diffusion.

320
Q

To minimize risk of infection associated with aerosol drug therapy, what should you do?

A

Sterilize the nebulizers between patients, Frequently replace in-use units, and rinse nebulizers with sterile water.

321
Q

To monitor a patient for the possibility of reactive bronchospasm during aerosol drug therapy what should u do?

A

Measure pre and post peak flow and/or %forced expiratory volume in 1 second, Auscultate for adventitious breath sounds, Observe patient’s response, and Communicate with the patient during therapy.

322
Q

Immediately after firing, the aerosol produced by most MDI’s are about how large?

A

35 um

323
Q

Most of the spray generated by the majority of MDI’s consist of what?

A

Propellant

324
Q

When fired inside the mouth what % of the drug dose delivered by a simple MDI deposits in the oropharynx?

A

80%

325
Q

Before inspiration and actuation of an MDI, the patient should exhale to which of the following?

A

FRC

326
Q

To ensure delivery of proper drug dosage with an MDI, which of the following must be done first?

A

The canister should be warmed to hand or body temperature and the canister should be vigorously shaken.

327
Q

What groups of patients are most likely to have difficulty using a simple MDI inhaler for aerosol drug therapy?

A

Patients that are in acute distress, infants and young children, and elderly persons.

328
Q

What is a potential limitation of flow triggered MDI devices?

A

The high flows necessary for actuation.

329
Q

What aerosol drug delivery system would you recommend against using with a toddler or small child?

A

MDI and SVN.

330
Q

Normally, when using a 50-psi flowmeter to drive a SVN, you set the flow at what?

A

6-8 L/min

331
Q

What device depends the patient’s inspiratory effort to dispense the dose?

A

DPI

332
Q

The key difference between an MDI holding chamber and a spacer is that the holding chamber incorporates what?

A

A one-way inspiratory valve.

333
Q

For which patients would you recommend against using a flow triggered MDI as the sole bronchodilator delivery system?

A

A patient that is likely to develop acute severe bronchospasm.

334
Q

What device would you select to deliver an aerosolized bronchodilator to a young child?

A

MDI, holding chamber, and mask.

335
Q

Proper use of a dry powder inhaler requires that the patient be able to do what?

A

Generate inspiratory flows of 60 L/min or higher.

336
Q

For what patient groups is the DPI for bronchodilator administration NOT recommended?

A

Infants and children under 5, patient’s with an acute bronchospastic episode.

337
Q

Exhalation into what device can result in loss of drug delivery?

A

Dry powder inhaler.

338
Q

SVN output drops after lowering the patient’s bed while giving a treatment but there is 3 mL of solution still left in reservoir. How can you correct this problem?

A

Reposition the patient so that the SVN is more upright.

339
Q

What happens as the pressure for flow delivered thru a SVN gets higher?

A

The treatment time becomes shorter, Particle size becomes smaller, Aerosol output becomes greater.

340
Q

To minimize a patient’s infection risk between drug treatment’s with an SVN, what would you do?

A

Rinse the SVN with sterile water; air dry.

341
Q

The physician has ordered an antiviral agent ribavirin (Virazole) to be administered by aerosol to an infant with bronchiolitis. Which device would you select?

A

SPAG – Small particle aerosol generator.

342
Q

What serious problems are associated with the delivery of Virazole using the SPAG?

A

Caregiver exposure to drug aerosol, drug precipitation in ventilator circuits.

343
Q

For maintenance administration of bronchodilators to adult patients with adequate inspiratory flow, which aerosol devices would u recommend?

A

DPI, and MDI with holding chamber.

344
Q

When assessing a patient’s response to bronchodilator therapy, you notice a decrease in wheezing accompanied by an overall decrease in breath sounds. What’s most likely the cause of this?

A

Increasing airway obstruction.

345
Q

An asthmatic in severe distress is admitted to ER. After full assessment and obtaining a pre-treatment baseline, you start the patient on albuterol with an SVN. When should you stop documentation and the treatment?

A

When the patient’s symptoms are relieved or when the PEFR/FEV1 in 1 second exceeds 70% of their personal best.

346
Q

What factor is most crucial in developing an effective program of aerosol drug self-administration in an adult patient requiring maintenance bronchodilator therapy?

A

Good patient education.

347
Q

What is the best way to confirm that an asthmatic patient can properly self-manage a newly prescribed aerosol drug therapy?

A

Have the patient provide a repeat or return demonstration.

348
Q

The physician orders continuous bronchodilator therapy with 1:200 albuterol for an asthma patient at a dosage of 20 mg/hr. How much 1:200 albuterol will be needed for the 1st hour of the treatment?

A

4 mL

349
Q

When using a chamber style adapter with an MDI to deliver a bronchodilator to a patient receiving mechanical ventilation, with what would you coordinate MDI firing?

A

The beginning of inspiration.